Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 2
2000 3
2001 1
2002 3
2003 4
2004 3
2005 3
2006 6
2007 5
2008 7
2009 5
2010 4
2011 6
2012 4
2013 6
2014 7
2015 11
2016 10
2017 6
2018 6
2019 4
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

97 results
Results by year
Filters applied: . Clear all
Page 1
Innate immune responses to trauma.
Huber-Lang M, Lambris JD, Ward PA. Huber-Lang M, et al. Nat Immunol. 2018 Apr;19(4):327-341. doi: 10.1038/s41590-018-0064-8. Epub 2018 Mar 5. Nat Immunol. 2018. PMID: 29507356 Free PMC article. Review.
Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.
Mastellos DC, Yancopoulou D, Kokkinos P, Huber-Lang M, Hajishengallis G, Biglarnia AR, Lupu F, Nilsson B, Risitano AM, Ricklin D, Lambris JD. Mastellos DC, et al. Eur J Clin Invest. 2015 Apr;45(4):423-40. doi: 10.1111/eci.12419. Epub 2015 Mar 9. Eur J Clin Invest. 2015. PMID: 25678219 Free PMC article. Review.
Compstatin was discovered as a cyclic peptide that inhibits complement activation by binding C3 and interfering with convertase formation and C3 cleavage. ...This review provides an up-to-date survey of the drug design effort placed on the compstatin family of C3 in
Compstatin was discovered as a cyclic peptide that inhibits complement activation by binding C3 and interfering with convertase forma
Complement-Dependent Mechanisms and Interventions in Periodontal Disease.
Hajishengallis G, Kajikawa T, Hajishengallis E, Maekawa T, Reis ES, Mastellos DC, Yancopoulou D, Hasturk H, Lambris JD. Hajishengallis G, et al. Front Immunol. 2019 Mar 12;10:406. doi: 10.3389/fimmu.2019.00406. eCollection 2019. Front Immunol. 2019. PMID: 30915073 Free PMC article. Review.
Safety profile after prolonged C3 inhibition.
Reis ES, Berger N, Wang X, Koutsogiannaki S, Doot RK, Gumas JT, Foukas PG, Resuello RRG, Tuplano JV, Kukis D, Tarantal AF, Young AJ, Kajikawa T, Soulika AM, Mastellos DC, Yancopoulou D, Biglarnia AR, Huber-Lang M, Hajishengallis G, Nilsson B, Lambris JD. Reis ES, et al. Clin Immunol. 2018 Dec;197:96-106. doi: 10.1016/j.clim.2018.09.004. Epub 2018 Oct 10. Clin Immunol. 2018. PMID: 30217791 Free PMC article.
We therefore set out to investigate the immune and biochemical profile of non-human primates under prolonged treatment with the C3 inhibitor compstatin (Cp40 analog). ...
We therefore set out to investigate the immune and biochemical profile of non-human primates under prolonged treatment with the C3 inhibitor …
New Analogs of the Complement C3 Inhibitor Compstatin with Increased Solubility and Improved Pharmacokinetic Profile.
Berger N, Alayi TD, Resuello RRG, Tuplano JV, Reis ES, Lambris JD. Berger N, et al. J Med Chem. 2018 Jul 26;61(14):6153-6162. doi: 10.1021/acs.jmedchem.8b00560. Epub 2018 Jul 3. J Med Chem. 2018. PMID: 29920096
Cp40, an analog of the peptide compstatin, inhibits all complement pathways at the level of the central component C3. We have further developed Cp40, using either PEGylation at the N-terminus or insertion of charged amino acids at the C-terminus. ...
Cp40, an analog of the peptide compstatin, inhibits all complement pathways at the level of the central component C3. We have further …
Thermodynamic studies on the interaction of the third complement component and its inhibitor, compstatin.
Katragadda M, Morikis D, Lambris JD. Katragadda M, et al. J Biol Chem. 2004 Dec 31;279(53):54987-95. doi: 10.1074/jbc.M409963200. Epub 2004 Oct 15. J Biol Chem. 2004. PMID: 15489226 Free article.
In the present study, isothermal titration calorimetry was employed to dissect the molecular forces that govern the interaction of compstatin with C3 using four different compstatin analogs. ...Finally, we propose based on the pK(a) values determined from the proton …
In the present study, isothermal titration calorimetry was employed to dissect the molecular forces that govern the interaction of compst
Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency.
Qu H, Magotti P, Ricklin D, Wu EL, Kourtzelis I, Wu YQ, Kaznessis YN, Lambris JD. Qu H, et al. Mol Immunol. 2011 Jan;48(4):481-9. doi: 10.1016/j.molimm.2010.10.004. Epub 2010 Nov 9. Mol Immunol. 2011. PMID: 21067811 Free PMC article.
Compstatin is a 13-residue disulfide-bridged peptide that inhibits a key step in the activation of the human complement system. Compstatin and its derivatives have shown great promise for the treatment of many clinical disorders associated with unbalanced complement
Compstatin is a 13-residue disulfide-bridged peptide that inhibits a key step in the activation of the human complement system. Co
Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin.
Sahu A, Soulika AM, Morikis D, Spruce L, Moore WT, Lambris JD. Sahu A, et al. J Immunol. 2000 Sep 1;165(5):2491-9. doi: 10.4049/jimmunol.165.5.2491. J Immunol. 2000. PMID: 10946275 Free article.
Herein, we describe the binding kinetics, structure-activity relationship, and biotransformation of Compstatin. Biomolecular interaction analysis using surface-plasmon resonance showed that Compstatin bound to native C3 and its fragments C3b and C3c, but not C3d. Wh …
Herein, we describe the binding kinetics, structure-activity relationship, and biotransformation of Compstatin. Biomolecular interact …
97 results
Jump to page
Feedback